ReviewBritish journal of clinical pharmacology2019
Optimising low-dose methotrexate for rheumatoid arthritis-A review.
Review in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Pharmacokinetics and bioequivalence evaluation of 2 oral formulations of methotrexate tablets in healthy Chinese volunteers under fasting and fed conditions.Naunyn-Schmiedeberg's archives of pharmacology · 2023Trial
- A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.Frontiers in immunology · 2022Trial
- Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases.Pharmacological reviews · 2026Review
- MTX pathway gene variants, erythrocyte methotrexate polyglutamates, and treatment outcomes in rheumatoid arthritis.Biomolecules & biomedicine · 2026Article
- Association of genetic polymorphisms on methotrexate toxicity in patients with rheumatoid arthritis.Archives of medical science : AMS · 2026Article
- Adjunctive zinc supplementation with methotrexate improves therapeutic outcomes in an animal model of arthritis.Inflammopharmacology · 2025Article
- Differential response of tissue engineered skeletal muscle from rheumatoid arthritis patients and healthy controls.Communications biology · 2025Article
- A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report.Case reports in dermatological medicine · 2025Article
- Translational Research in Oral Lichen Planus: From Laboratory Discoveries to Clinical Applications.Cureus · 2024Review
- A reconfigurable integrated smart device for real-time monitoring and synergistic treatment of rheumatoid arthritis.Science advances · 2024Article
- An acute herb-drug interaction of Magnoliae Officinalis Cortex with methotrexate via inhibiting multidrug resistance-associated protein 2.Journal of food and drug analysis · 2024Article
- Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes.BMC rheumatology · 2024Article
- Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.Frontiers in pharmacology · 2024Article
- Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats.Iranian journal of basic medical sciences · 2024Article
- Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis.Drug delivery · 2023Article
- Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.Current rheumatology reports · 2023Review
- L-methionine protects against nephrotoxicity induced by methotrexate through modulation of redox status and inflammation.Redox report : communications in free radical research · 2023Article
- Vaccines prevent reinduction of rheumatoid arthritis symptoms in collagen-induced arthritis mouse model.Drug delivery and translational research · 2023Article
- Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease.Indian journal of ophthalmology · 2023Review
- Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients.Current opinion in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.